Immupharma PLC - pharmaceutical company - Executes agreement to subscribe GBP250,000 for 2.6 million shares in Incanthera equal to its IPO price of 9.5 pence. Following this subscription, ImmuPharma will hold 9.9 million shares in Incanthera, representing a 15.4% stake. "ImmuPharma notes two recent positive announcements from Incanthera regarding studies of its lead product Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers," says Immupharma.
Current stock price: 11.325 pence
Year-to-date change: down 29%
By Lucy Heming;Â email@example.com
Copyright 2020 Alliance News Limited. All Rights Reserved.